Search

Your search keyword '"Katsomitrou, Vaitsa"' showing total 7 results
Start Over Author "Katsomitrou, Vaitsa"
7 results on '"Katsomitrou, Vaitsa"'

2. Improvement in mortality of hospitalized patients with hematological malignancies in the 2nd wave of COVID-19 in the UK: experience of a large London NHS trust

Author

Hinton, Richard, primary, Nesr, George, additional, Garnett, Catherine, additional, Foldes, David, additional, McCay, Joel James Robert, additional, Medland, Rachael, additional, Kagdi, Huseini, additional, Katsomitrou, Vaitsa, additional, Sim, Hau Wui, additional, Gandhi, Sameer, additional, Parcharidou, Agapi, additional, and Arami, Siamak, additional

Published
2021
Full Text
View/download PDF

4. Outcome of hospitalized patients with hematological malignancies and COVID-19 infection in a large urban healthcare trust in the United Kingdom

Author

Garnett, Catherine, primary, Foldes, David, additional, Bailey, Chris, additional, Nesr, George, additional, Hui, Tracy, additional, Hinton, Richard, additional, Gurung, Kamala, additional, Phillips, James, additional, Saleem, Zahbia, additional, Koshy, Rincy, additional, Aduwa, Elvis, additional, Colis, Marife, additional, Bimolah, Ravi, additional, Katsomitrou, Vaitsa, additional, Arami, Siamak, additional, and Kagdi, Huseini, additional

Published
2020
Full Text
View/download PDF

5. Improvement in mortality of hospitalized patients with hematological malignancies in the 2nd wave of COVID-19 in the UK: experience of a large London NHS trust.

Author

Hinton, Richard, Nesr, George, Garnett, Catherine, Foldes, David, McCay, Joel James Robert, Medland, Rachael, Kagdi, Huseini, Katsomitrou, Vaitsa, Sim, Hau Wui, Gandhi, Sameer, Parcharidou, Agapi, and Arami, Siamak

Subjects
HEMATOLOGIC malignancies, HOSPITAL patients, HEART failure, LOW-molecular-weight heparin, PLASMA cell diseases
Abstract

In the second wave 57.8% (37/64) of patients received dexamethasone, 39.6% (25/64) of patients received remdesivir and one patient received tocilizumab. Patients with hematological malignancies who contract COVID-19 have been identified as having a high overall mortality rate of between 33 and 37% in a number of large studies from the first wave of COVID-19 infections in the first half of 2020 [[1], [3]]. In terms of hematological diagnoses, 34 patients had a lymphoid malignancy, 23 patients had a myeloid malignancy and 12 patients had a plasma cell disorder. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. [Extracted from the article]

Published
2022
Full Text
View/download PDF

6. Outcome of hospitalized patients with hematological malignancies and COVID-19 infection in a large urban healthcare trust in the United Kingdom.

Author

Garnett, Catherine, Foldes, David, Bailey, Chris, Nesr, George, Hui, Tracy, Hinton, Richard, Gurung, Kamala, Phillips, James, Saleem, Zahbia, Koshy, Rincy, Aduwa, Elvis, Colis, Marife, Bimolah, Ravi, Katsomitrou, Vaitsa, Arami, Siamak, and Kagdi, Huseini

Subjects
COVID-19, MONOCLONAL gammopathies, HOSPITAL patients, MEDICAL care
Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results